| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11095-006-0162-4 |
| P698 | PubMed publication ID | 16715363 |
| P2093 | author name string | Yoshinori Aso | |
| Shinji Yamashita | |||
| Yoshiki Hayashi | |||
| Kiyohiko Sugano | |||
| Atsuko Higashida | |||
| Minoru Machida | |||
| Ryusuke Takano | |||
| P2860 | cites work | Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. | Q30482391 |
| Drug-like properties and the causes of poor solubility and poor permeability | Q30660926 | ||
| Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data | Q31461215 | ||
| Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards | Q33935245 | ||
| In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs | Q34061188 | ||
| Physiological measurements of luminal stirring in the dog and human small bowel | Q34263264 | ||
| Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration | Q34417089 | ||
| Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers | Q34692201 | ||
| pH-related changes in the absorption of dipyridamole in the elderly | Q34724447 | ||
| A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation | Q35826817 | ||
| Comparison of canine and human gastrointestinal physiology | Q38165787 | ||
| Use of carbon monoxide to measure luminal stirring in the rat gut. | Q40926929 | ||
| Human intestinal permeability | Q41741549 | ||
| Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration | Q43665637 | ||
| Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs | Q44149118 | ||
| High-throughput measurement of pKa values in a mixed-buffer linear pH gradient system | Q44352306 | ||
| pH and energy dependent transport of ketoprofen across rat jejunum in vitro | Q44499151 | ||
| Absorption characteristics of solid dispersed and micronized griseofulvin in man. | Q44607242 | ||
| High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry | Q44675958 | ||
| Absorption potential: estimating the fraction absorbed for orally administered compounds | Q45245550 | ||
| In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media | Q45284885 | ||
| Prediction of oral drug absorption in humans by theoretical passive absorption model | Q46390763 | ||
| Molecular properties of WHO essential drugs and provisional biopharmaceutical classification | Q46439269 | ||
| Membrane transport of drugs in different regions of the intestinal tract of the rat. | Q50754829 | ||
| Analysis of conjugated and unconjugated bile acids in serum and jejunal fluid of normal subjects. | Q51632704 | ||
| An integrated model for determining causes of poor oral drug absorption. | Q52082693 | ||
| Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs. | Q52208041 | ||
| Increased gastric pH and the bioavailability of fluconazole and ketoconazole. | Q52450491 | ||
| Closed rat jejunal segment in situ: role of pre-epithelial diffusion resistance (unstirred layer) in the absorption process and model analysis. | Q54412263 | ||
| Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs | Q59237519 | ||
| Influence of food on the absorption of phenytoin in man | Q66923473 | ||
| Spironolactone. II. Bioavailability | Q67443833 | ||
| Duodenal bile acids after a test meal | Q68804029 | ||
| Mixing-tank model for predicting dissolution rate control or oral absorption | Q70033000 | ||
| Influence of viscosity and solubilization on dissolution rate | Q70450399 | ||
| Effect of food and a monoglyceride emulsion formulation on danazol bioavailability | Q70660652 | ||
| Clinical pharmacokinetics of dipyridamole | Q70919544 | ||
| The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum | Q71252169 | ||
| Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine | Q71699411 | ||
| Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets | Q72058606 | ||
| Physiological parameters in laboratory animals and humans | Q72935917 | ||
| The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds | Q73364551 | ||
| Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells | Q73682351 | ||
| P433 | issue | 6 | |
| P921 | main subject | computer simulation | Q925667 |
| P304 | page(s) | 1144-1156 | |
| P577 | publication date | 2006-05-25 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. | |
| P478 | volume | 23 |
| Q92557489 | A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH |
| Q37471061 | A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans |
| Q34487999 | A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation |
| Q40672523 | Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics |
| Q58593567 | Application of a refined Developability Classification System |
| Q36232481 | Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling |
| Q100568976 | Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report |
| Q88918124 | Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system |
| Q37325589 | CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling |
| Q38112181 | Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms |
| Q94538992 | Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report |
| Q42140603 | Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques |
| Q46465979 | Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. |
| Q93257496 | Evaluation of Differences in Dosage Form Performance of Generics using BCS-Based Biowavier Specifications and Biopharmaceutical Modeling - Case Examples Amoxicillin and Doxycycline |
| Q34761052 | Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis |
| Q89115461 | Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies |
| Q46573336 | Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example |
| Q39773047 | In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. |
| Q37126427 | In vitro-in vivo correlation of efavirenz tablets using GastroPlus® |
| Q89910071 | In vitro/vivo assessment of praziquantel nanocrystals: Formulation, characterization, and pharmacokinetics in beagle dogs |
| Q52735069 | Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization. |
| Q90191240 | Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen |
| Q41526373 | Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence |
| Q58617160 | Integration of Precipitation Kinetics From an In vitro, Multicompartment Transfer System and Mechanistic Oral Absorption Modeling for Pharmacokinetic Prediction of Weakly Basic Drugs |
| Q52708095 | Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables. |
| Q57297034 | Mechanistic Study of Belinostat Oral Absorption from Spray Dried Dispersions |
| Q38848902 | Mechanistic prediction of food effects for Compound A tablet using PBPK model. |
| Q37406577 | Modeling and Simulation of Intracellular Drug Transport and Disposition Pathways with Virtual Cell |
| Q91704027 | Multicomponent Crystal of Mefenamic Acid and N-Methyl-d-Glucamine: Crystal Structures and Dissolution Study |
| Q57349944 | Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improvein vitrodissolution andin vivooral absorption |
| Q46814392 | Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation |
| Q39786216 | Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning |
| Q37054214 | Pharmaceutical quality by design: product and process development, understanding, and control |
| Q47375821 | Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model |
| Q41989355 | Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes |
| Q39567801 | Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib |
| Q89964117 | Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film |
| Q38959281 | Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine |
| Q41989632 | Pluronic and tetronic copolymers with polyglycolyzed oils as self-emulsifying drug delivery systems |
| Q90854096 | Population Balance Model for Simulation of the Supersaturation-Precipitation Behavior of Drugs in Supersaturable Solid Forms |
| Q37149095 | Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects |
| Q93037397 | Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir |
| Q60107344 | Predicting the Effect of Fed-State Intestinal Contents on Drug Dissolution |
| Q92580245 | Prediction Accuracy of Mechanism-Based Oral Absorption Model for Dogs |
| Q92168392 | Prediction Characteristics of Oral Absorption Simulation Software Evaluated Using Structurally Diverse Low-Solubility Drugs |
| Q36885247 | Prediction of human pharmacokinetics--gastrointestinal absorption |
| Q38177366 | Pros and cons of methods used for the prediction of oral drug absorption. |
| Q46534443 | Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. |
| Q46297172 | Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations |
| Q38959936 | Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development. |
| Q47327052 | Selecting the particle size distribution for drugs with low water solubility - mathematical model |
| Q48368186 | Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release. |
| Q38534506 | Small Volume Dissolution Testing as a Powerful Method during Pharmaceutical Development |
| Q50090792 | Study the influence of formulation process parameters on solubility and dissolution enhancement of efavirenz solid solutions prepared by hot-melt extrusion: a QbD methodology. |
| Q96124374 | Suitability of the z-Factor for Dissolution Simulation of Solid Oral Dosage Forms: Potential Pitfalls and Refinements |
| Q47665783 | The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene |
| Q84990410 | The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development |
| Q39884135 | The Evaluation of In Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media. |
| Q51405119 | The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs. |
| Q50636753 | Theoretical Investigation of Dissolution Test Criteria for Waiver of Clinical Bioequivalence Study. |
| Q37126489 | Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 |
| Q37265500 | Towards quantitative prediction of oral drug absorption |
| Q34503553 | Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. |
| Q38799352 | Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling |
Search more.